| Dr David Rollins Pruett, MD | |
|
9205 Sw Barnes Rd, Portland, OR 97225-6603 | |
| (503) 297-6334 | |
| (503) 297-2360 |
| Full Name | Dr David Rollins Pruett |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 9205 Sw Barnes Rd, Portland, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063582070 | NPI | - | NPPES |
| 151093 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD20301 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Rollins Pruett, MD 9340 Sw Barnes Rd, Suite 202, Portland, OR 97225-6623 Ph: (503) 297-6334 | Dr David Rollins Pruett, MD 9205 Sw Barnes Rd, Portland, OR 97225-6603 Ph: (503) 297-6334 |
News Archive
The National Institutes of Health today has launched three pre-clinical projects to advance potential new treatments for acute radiation syndrome, brain injury following cardiac arrest and a rare blood disorder called beta thalassemia.
Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.
"Circumcision reduces a man's risk of acquiring and transmitting HIV and other sexually transmitted diseases, and now researchers have found a possible explanation: the procedure reduces the quantity and diversity of bacteria at the head of the penis," the New York Times' "Well" blog reports (Bakalar, 4/18).
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.
› Verified 4 days ago
Kimberly Lauren Imbesi, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8211 Fax: 503-346-8021 | |
Dr. Hani Darwich, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 10123 Se Market St, Portland, OR 97216 Phone: 503-252-2004 | |
Dr. Robert Thomas Martin, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-297-6334 Fax: 503-297-2360 | |
Dr. Jessica Slim, M.D., M.P.H. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-7551 Fax: 503-494-4997 | |
Robert Barriatua, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10123 Se Market St, Portland, OR 97216 Phone: 503-252-2004 | |
Carolyn N Rhett, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1015 Nw 22nd Ave, Portland, OR 97210 Phone: 503-413-7260 | |
Dr. Ross Emery Bryan Iv, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Ohsu Dept Of Emergency Medicine Cdw-em, Portland, OR 97239 Phone: 503-494-1270 |